Category Archives: Reasearch

08Sep/23

Economist Impact research shows climate change associations-including increasing heatwaves and pollen-are affecting lung health

September 8, 2023ReasearchAir pollution, Chiesi Group, Climate forcing, Determinants of health, Health equity, Impact, Occupational safety and health, Pollution, The Economist Groupadmin

Today Economist Impact, an arm of The Economist Group that works with organisations globally to further their missions, released research supported by Chiesi Group, a pharmaceutical company, exploring the links between air quality, health inequalities and lung health. A survey of 500 people found that, despite reductions in the concentration of key air pollutants, poor air quality negatively affects symptoms, overall health and quality of life for people living with lung conditions. Continue reading

18Aug/23

Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval

August 18, 2023ReasearchClinical research, Clinical trial, Food and Drug Administration, London, Medical device, Patient recruitment, Pharmaceutical industry, Sweden, United Kingdom, Ventricular assist deviceadmin

Today, Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024. Continue reading

27Jul/23

Mount Sinai Researchers Uncover How Mammary Glands Control Overall Energy Balance and Fat Metabolism

July 27, 2023ReasearchAdipose tissue, Breast, Breast anatomy, Breast reduction, Breastfeeding, Connective tissue, Icahn, Mammary gland, Nutrition, Obesity, Risk factors for breast canceradmin

An Icahn School of Medicine at Mount Sinai study sheds light on the intricate interplay between mammary adipose (fat) tissue and breast health, and offers exciting possibilities for understanding breast development, lactation, cancer, and obesity and related metabolic disorders. Continue reading

25Jul/23

Does a woman’s menstrual cycle affect her athletic performance? Here’s what the science says

July 25, 2023ReasearchBody Literacy, Creative Commons, Hormonal contraception, Menstrual cycle, Menstrual suppression, Menstruation, Michael Pengelly, Midwifery, Ovulation, progesterone, Sara Chica-Latorreadmin

Sara Chica-Latorre, University of Canberra and Michael Pengelly, University of Canberra

During the Women’s FIFA World Cup, it has been wonderful to see the spotlight turn to female athletes.

There’s always been more research on male athletes compared to female athletes, but the gap is narrowing.

One thing we still don’t know enough about is the effect of the menstrual cycle on athletic performance.

Continue reading →

18Jul/23

ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023

July 18, 2023ReasearchAAIC, Alzheimer's Association, Alzheimer's disease, Amsterdam, Clinical trial, Donanemab, Eli Lilly, Eli Lilly and Company, Monoclonal antibodies, Netherlandsadmin

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment. The full Phase 3 data was reported at the Alzheimer’s Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online. The data were simultaneously published in the Journal of the American Medical Association. Continue reading

11Apr/23

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

April 11, 2023ReasearchAcademic disciplines, Algorithm, Articles, Artificial intelligence, Chicago, Health, Health informatics, Healthcare Information and Management Systems Society, Medical algorithm, Medical diagnosis, Medical terminology, OTC Markets Group, Rog, United Statesadmin

Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces its navify® Algorithm Suite, a single platform hosting a library of digital medical algorithms that generate patient-centric insights and can aid earlier diagnosis of cancer and other conditions per intended use, at the HIMSS Global Conference in Chicago, USA, from April 17- 21, 2023. Continue reading

18Mar/23

New Co-Authored Study Opens New Doors to Quantum-Powered Machine Learning and Medical Diagnostics

March 18, 2023ReasearchAcademic disciplines, Articles, Computational complexity theory, Diabetes, Diabetic retinopathy, Emerging technologies, Quantum computing, Retinopathy, Theoretical computer scienceadmin

QC Ware, a leading quantum software and services company, announced today that a joint research project with one of the world’s leading biotechnology companies uncovered new discoveries in medical imaging analysis and diagnostics, leveraging quantum computing to better detect the presence and type of diabetic retinopathy. Continue reading

13Mar/23

Pfizer Invests $43 Billion to Battle Cancer

March 13, 2023ReasearchAlbert Bourla, Antibody-drug conjugate, Antineoplastic drugs, Articles, ASTELLAS, Astellas Pharma, BOTHELL, brentuximab vedotin, Canada, Centerview Partners, Centerview Partners LLC, China, Chris Boshoff, David Caouette, David Epstein, Douglas, Genmab, Guggenheim Securities LLC, Health, Investment banks, Investor Call Details Pfizer Inc., Japan, Life sciences, Macau, Merck, New York, Pfizer, Pfizer Inc., Pharmaceutical industry, Sanofi S.A., SeaGen, Seagen Inc., Seattle, SULLIVAN & CROMWELL LLP, Switzerland, Taiwan, Takeda, United States, WACHTELL, LIPTON, ROSEN & KATZ, Washington, zai labadmin

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion
Proposed combination enhances Pfizer’s position as a leading company in Oncology
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today

NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction. Continue reading →

11Mar/23

New Research in JNCCN Highlights the Negative Impact of Continued Exclusion of Racial Groups from Research on Cancer Genomics

March 11, 2023ReasearchBranches of biology, Cancer, Clinical medicine, Genetic testing, Medical genetics, Medicine, National Comprehensive Cancer Network, Prostate cancer, Prostate cancer screening, RTT, War on Canceradmin

New research in the March 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with cancer. In a first-of-its-kind study, the researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer to find evidence for increased and potentially unique genetic testing recommendations. Continue reading

06Mar/23

icometrix & Queen Mary University of London receive prestigious AI Award from the National Institute for Health and Care Research (NIHR) to investigate the impact of AI applied to MRI in the care of people with multiple sclerosis (MS)

March 6, 2023ReasearchArticles, Artificial intelligence, Computational neuroscience, Contents, Cybernetics, Magnetic resonance imaging, Queen Mary University of London, Technologyadmin

icometrix is proud to announce that, together with Queen Mary University of London (QMUL), it has been awarded the prestigious AI Award in Health and Care. This collaborative program will investigate the impact of AI on the assessment of MRI and decision making in the context of multi-disciplinary team meetings for people with MS. It is hoped that this research will lead to better care for people with MS (pwMS). Continue reading

Category: Reasearch